Entity

Time filter

Source Type

COLLEGE STATION, TX, United States

Grant
Agency: Department of Defense | Branch: Office of the Secretary of Defense | Program: STTR | Phase: Phase II | Award Amount: 749.99K | Year: 2015

Due to the limited amount of rhenium present in the earths crust (approximately 1-2 part per billion) there is a significant benefit to be realized in recovering for reuse the rhenium from scrap material, spent catalysts, or end-of-life superalloys. Rhenium is found in molybdenum-copper porphyry deposits. If rhenium is present in ore that is processed, it will show up in the resulting molybdenum concentrate and will be retrieved in the molybdenum roasting process. Since there are no primary deposits of rhenium, the method in which it is processed is directly related to method in which molybdenum is produced. Very little rhenium is actually processed and isolated each year as compared to the millions of tons of copper and millions of pounds of molybdenum that are extracted from the same copper deposits. Opportunities exist for enhancing rhenium yield through technological improvements in discrete steps in the recovery process. Due to rheniums excellent high temperature properties (high creep resistance, high melting point, etc.) it is widely used as an alloying agent for high temperature applications including: Pt-Re petroleum reforming catalysts (20% current market use) Super alloys in high temperature turbine engines (70% current market use) Electromagnets, thermocouples, x-ray tube targets, and various others (10% current market use) As of 2010, the USGS reports that all platinum-rhenium petroleum reforming catalysts are recycled [1]. Information on the recycling rates of the remaining 80% of rhenium products is quite limited, although it is postulated to be sufficiently lower than the Pt-Re catalyst industry. Thus, the largest area for potential research may be the recovery and subsequent reuse of the rhenium in superalloys and various rhenium containing products.


Grant
Agency: Department of Defense | Branch: Defense Health Program | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2016

Between Operation Iraqi Freedom, Operation Enduring Freedom, and Operation New Dawn, the total number of U.S. Casualties (those Wounded in Action) has exceeded 52,000 as of January 30, 2015. These numbers point to the fact that active warfighters in the


Grant
Agency: Department of Homeland Security | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 760.00K | Year: 2015

Lynntech, Inc. proposes the use of a novel oxidant as a powdered concentrate, that when dissolved in water, yields a potent sporicidal solution capable of reducing spores by greater than 6-logs on a variety of surfaces. The sporicidal formulation will be tested on concrete, wood, galvanized metal, glass, plastic and painted wallboard to determine if the formulation will reduce spores but not harm the contacted surfaces. The formulation will include gelling agents to increase the formulation viscosity to better adherence to walls and ceilings for longer contact times. The formulation will also contain additives to increase efficacy of spore coat penetration and long term shelf life. Potential markets include first responders, military, medical and biomedical industry, and agriculture and industrial sectors for clean up and first response remediation. Alternative end user interest might include clandestine drug synthesis laboratory clean-up companies.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 294.00K | Year: 2016

DESCRIPTION provided by applicant Chronic wounds such as diabetic foot ulcers DFU represent a major area of medical concern Of the approximately million diabetic patients in the USA almost million display these types of partial thickness wounds More than diabetes related lower extremity amputations LEAs are conducted annually in the USA alone Fully eighty five percent of LEAs in diabetic patients are preceded by biofilm phenotype infections in foot ulceration It is recently being recognized that an added primary impediment to the healing of DFU is such biofilm phenotype infections DFU entrenched biofilms consist of polymicrobial populations of cells encased in hydrated extracellular polymeric substances that are tightly attached to the wound surface The biofilm phenotype imparts considerable resilience to these infections and current modalities including surgical debridement topical and systemic antimicrobials topical biocides and topical anti biofilm agents have major limitations in effectively killing resident bacteria and more clinically importantly completely removing biofilm from the wound bed Traditional wound management modalities such as grafts advanced bioengineered dressings and negative pressure wound therapy cannot be applied with any expectation of success without first extensively debriding the wound Lynntech Inc in collaboration with Texas Tech University Health Sciences Center and in consultation with the Southwest Regional Wound Care Center proposes to develop an innovative inexpensive and compact chronic wound management device termed SNAPCAP which has the potential to be applied to bioburdened chronic wounds to overcome the limitations of existing modalities This device will be engineered to rapidly and reagentlessly remove biofilm from the wound bed without relying on surgical debridement and to subsequently apply a follow on therapy that has the potential to improve the healing of debrided chronic wounds During this Phase I SBIR effort our specific Aims are to design and fabricate prototype SNAPCAP devices optimize SNAPCAP performance for biofilm removal and epithelial gap reduction in vitro using a human skin equivalent tissue model of infected wound healing and preliminarily evaluate the utility of SNAPCAP in vivo using a murine model of splinted full thickness polymicrobial biofilm infected diabetic wound healing The successful completion of these specific Aims should demonstrate ample feasibility of this innovative new chronic wound management approach and will allow us to plan more comprehensive technology development and commercialization thrusts in a future follow on Phase II effort The eventual commercial availability of SNAPCAP devices is likely to sustain high positive impact for the patient populace suffering from chronic wounds that are bioburdened in particular polymicrobial biofilm infected DFU PUBLIC HEALTH RELEVANCE The potential long term impact of this SBIR effort is a new paradigm in the clinical management of chronic wounds such as polymicrobial biofilm infected DFU Our envisioned automated SNAPCAP wound treatment devices may provide significant clinical benefit for the millions of diabetic patients suffering from bio burdened DFU This approach may have the potential to greatly improve the quality of life of patients suffering from DFU while simultaneously lowering the costs pain and risks associated with routine maintenance debridement procedures


Grant
Agency: Department of Defense | Branch: Defense Health Program | Program: SBIR | Phase: Phase II | Award Amount: 994.07K | Year: 2015

Our warfighters are at great risk of large area burn wounds from incendiary munitions and improvised devices. Limitations of currently utilized field dressings greatly increase incidences of wound infection, further deterioration, shock and fatalities during CASEVAC to higher echelon levels of military medical care. During Phase I, Lynntech demonstrated strong proof-of-concept in vitro for a novel approach, termed StABL-SD, to rapidly and reagentlessly sterilize and simultaneously encase burn wounds within a thin film dressing, which provides prophylaxis against infectious pathogens, controlled oxygen and vapor transport, and active support for proliferative wound healing. In this proposed Phase II effort, we will fabricate prototype StABL-SD devices and demonstrate their utility in vivo using an accepted porcine model of thermal burn wound healing. StABL-SD can be utilized by minimally trained personnel in the theater of battle to stabilize burn casualties immediately after wounding for safer, non-deteriorative and more comfortable transport encased in the protective film dressing. StABL-SD is of direct relevance to the unmet DOD need for improving warfighter survivability during transport stateside while simultaneously improving eventual treatment outcomes. Commercial deployment of StABL-SD in future Phases will enable improved military and civilian burn casualty stabilization for successful and survivable transport to burn units.

Discover hidden collaborations